✦ LIBER ✦

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer

✍ Scribed by J.D. Hurt; D.L. Richardson; L.G. Seamon; J.F. Fowler; L.J. Copeland; D.E. Cohn; E. Eisenhauer; R. Salani; D.M. O'Malley

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Addition of bevacizumab to weekly paclit

✍ David M. O'Malley; Debra L. Richardson; Patrick S. Rheaume; Ritu Salani; Eric L. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 249 KB

Addition of bevacizumab to weekly paclit

✍ Maurie Markman 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Response to letter to the editor in resp

✍ David M. O'Malley 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 123 KB

Salvage treatment in metastatic breast c

✍ Aris Polyzos; Kostas Kalbakis; Nikolaos Kentepozidis; Stylianos Giassas; Antonia 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 176 KB

Circulating tumor cells predict progress

✍ Andres Poveda; Stanley B. Kaye; Robert McCormack; Songbai Wang; Trilok Parekh; D 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 303 KB

Phase II study of gemcitabine and weekly

✍ Agustin A Garcia; Anne O'Meara; Ashim Bahador; Grace Facio; Susan Jeffers; Dae-Y 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 185 KB